Moleculin presents cardiac safety data for Annamycin at major European cancer conference

Filed May 12, 2026 · Period ending May 12, 2026 · ~1 min read

Key Changes

• medium

  Company published abstract at EHA 2026 Congress highlighting favorable cardiac safety profile of Annamycin, its lead drug candidate for relapsed/refractory acute myeloid leukemia currently in late-stage development.

  Item 7.01 verify on EDGAR →
• medium

  Cardiac safety is a critical differentiator for anthracycline cancer drugs, as traditional versions can cause heart damage; positive safety data could strengthen Annamycin's competitive position if approved.

  Press Release verify on EDGAR →